...
首页> 外文期刊>BMC Pediatrics >Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
【24h】

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment

机译:南非艾滋病毒感染儿童在接受利托那韦增强洛匹那韦和奈韦拉平治疗后对抗逆转录病毒治疗的反应中的性别差异

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background While studies of HIV-infected adults on antiretroviral treatment (ART) report no sex differences in immune recovery and virologic response but more ART-associated complications in women, sex differences in disease progression and response to ART among children have not been well assessed. The objective of this study was to evaluate for sex differences in response to ART in South African HIV-infected children who were randomized to continue ritonavir-boosted lopinavir (LPV/r)-based ART or switch to nevirapine-based ART. Methods ART outcomes in HIV-infected boys and girls in Johannesburg, South Africa from 2005–2010 were compared. Children initiated ritonavir-boosted lopinavir (LPV/r)-based ART before 24?months of age and were randomized to remain on LPV/r or switch to nevirapine-based ART after achieving viral suppression. Children were followed for 76?weeks post-randomization and then long-term follow up continued for a minimum of 99?weeks and maximum of 245?weeks after randomization. Viral load, CD4 count, lipids, anthropometrics, drug concentrations, and adherence were measured at regular intervals. Outcomes were compared between sexes within treatment strata. Results A total of 323 children (median age 8.8?months, IQR 5.1-13.5), including 168 boys and 155 girls, initiated LPV/r-based ART and 195 children were randomized. No sex differences in risk of virological failure (confirmed viral load >1000 copies/mL) by 156?weeks post-randomization were observed within either treatment group. Girls switched to nevirapine had more robust CD4 count improvement relative to boys in this group through 112?weeks post-randomization. In addition, girls remaining on LPV/r had higher plasma concentrations of ritonavir than boys during post-randomization visits. After a mean of 3.4?years post-randomization, girls remaining on LPV/r also had a higher total cholesterol:HDL ratio and lower mean HDL than boys on LPV/r. Conclusions Sex differences are noted in treated HIV-infected children even at a young age, and appear to depend on treatment regimen. Future studies are warranted to determine biological mechanisms and clinical significance of these differences. Trial registration ClinicalTrials.gov Identifier: NCT00117728
机译:背景技术尽管对接受HIV感染的成年人进行抗逆转录病毒治疗(ART)的研究报告说,女性的免疫恢复和病毒学应答方面没有性别差异,但女性的ART相关并发症更多,但尚未很好评估儿童疾病进展和对ART的反应方面的性别差异。这项研究的目的是评估南非艾滋病毒感染儿童中对ART反应的性别差异,这些儿童被随机分配继续使用以利托那韦为基础的洛匹那韦(LPV / r)为基础的ART,或转用基于奈韦拉平的ART。方法比较了南非约翰内斯堡2005-2010年艾滋病毒感染的男孩和女孩的ART结果。儿童在24周龄之前开始使用利托那韦增强的洛匹那韦(LPV / r)进行抗逆转录病毒治疗,并在达到病毒抑制后被随机分组​​,以继续使用LPV / r或改用基于奈韦拉平的抗逆转录病毒疗法。随机分配后,对儿童进行了76周的随访,然后在随机分组后继续进行了至少99周和245周的长期随访。定期测量病毒载量,CD4计数,脂质,人体测量学,药物浓度和依从性。比较治疗层次中性别之间的结果。结果共有323名儿童(中位年龄8.8个月,IQR 5.1-13.5)发起了基于LPV / r的抗逆转录病毒治疗,其中168名男孩和155名女孩被随机分配,其中195名儿童被随机分配。在两个治疗组中,在随机化后156周未观察到病毒学失败风险的性别差异(确认病毒载量> 1000拷贝/ mL)。在随机分组后的112周内,转用奈韦拉平的女孩相对于该组男孩的CD4计数改善更为强劲。此外,在随机后访视期间,保持LPV / r的女孩血浆利托那韦的血浆浓度高于男孩。经过平均3.4年的随机分组后,仍然保持LPV / r的女孩比LPV / r的男孩具有更高的总胆固醇:HDL比和平均HDL更低。结论即使在很小的年龄,在接受过HIV感染的儿童中仍存在性别差异,并且似乎取决于治疗方案。有必要进行进一步的研究以确定这些差异的生物学机制和临床意义。试验注册ClinicalTrials.gov标识符:NCT00117728

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号